image
Healthcare - Biotechnology - NASDAQ - US
$ 1.04
0 %
$ 23.3 M
Market Cap
0.13
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BOLD stock under the worst case scenario is HIDDEN Compared to the current market price of 1.04 USD, Boundless Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BOLD stock under the base case scenario is HIDDEN Compared to the current market price of 1.04 USD, Boundless Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BOLD stock under the best case scenario is HIDDEN Compared to the current market price of 1.04 USD, Boundless Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BOLD

image
$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
0 REVENUE
0.00%
-73.3 M OPERATING INCOME
-33.71%
-65.4 M NET INCOME
-32.22%
-60.8 M OPERATING CASH FLOW
-29.85%
-26.1 M INVESTING CASH FLOW
31.78%
89.8 M FINANCING CASH FLOW
-8.25%
0 REVENUE
0.00%
-17.3 M OPERATING INCOME
5.13%
-15.8 M NET INCOME
4.20%
-14.5 M OPERATING CASH FLOW
6.64%
3.06 M INVESTING CASH FLOW
67.86%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Boundless Bio, Inc.
image
Current Assets 154 M
Cash & Short-Term Investments 152 M
Receivables 0
Other Current Assets 2.28 M
Non-Current Assets 52 M
Long-Term Investments 0
PP&E 51.4 M
Other Non-Current Assets 659 K
73.70 %24.88 %Total Assets$206.4m
Current Liabilities 8.14 M
Accounts Payable 1.27 M
Short-Term Debt 0
Other Current Liabilities 6.86 M
Non-Current Liabilities 47.6 M
Long-Term Debt 47.6 M
Other Non-Current Liabilities 0
12.30 %85.41 %Total Liabilities$55.8m
EFFICIENCY
Earnings Waterfall Boundless Bio, Inc.
image
Revenue 0
Cost Of Revenue 1.09 M
Gross Profit 0
Operating Expenses 73.3 M
Operating Income -73.3 M
Other Expenses -7.9 M
Net Income -65.4 M
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)0(1m)0(73m)(73m)8m(65m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-43.39% ROE
-43.39%
-31.67% ROA
-31.67%
-36.95% ROIC
-36.95%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Boundless Bio, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -65.4 M
Depreciation & Amortization 1.09 M
Capital Expenditures -2.54 M
Stock-Based Compensation 7.52 M
Change in Working Capital -1.68 M
Others -4.08 M
Free Cash Flow -63.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Boundless Bio, Inc.
image
BOLD has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Boundless Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that   Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference. globenewswire.com - 3 weeks ago
Boundless Bio Announces Portfolio Prioritization and Runway Extension Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825  and new development candidate, BBI-940, for novel kinesin program globenewswire.com - 1 month ago
BOLD. ZESTY. ALWAYS ELECTRIC: SMIRNOFF INTRODUCES AWARD-WINNING ELECTRIC GUAVA WITH A FLAVOR-FORWARD MIAMI TAKEOVER FEATURING GENRE-BLENDING ARTISTS AND CULTURAL TASTEMAKERS COCO & BREEZY The new limited-edition offering blending the flavors of juicy guava and zesty ginger haspicked up multiple awards before officially hitting shelves in June NEW YORK , May 21, 2025 /PRNewswire/ -- From the brand that brought the sweet and spicy sensation of Smirnoff Spicy Tamarind comes its latest vibrant flavor: NEW Smirnoff Electric Guava. The limited-edition vodka specialty is already turning heads and activating tastebuds, earning top honors including Double Gold at the San Francisco World Spirits Competition and Platinum at the L.A. prnewswire.com - 1 month ago
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know Boundless Bio, Inc. (BOLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 month ago
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 globenewswire.com - 1 month ago
New Strong Sell Stocks for May 1st AMPY, ASTS and BOLD have been added to the Zacks Rank #5 (Strong Sell) List on May 1, 2025. zacks.com - 1 month ago
JOIN LOWE'S BOLD MISSION TO SHARE ONE MILLION THANKS FOR THOSE RESPONDING TO DISASTERS Lowe's associates use symbolic store re-opening to call on help across the country to #BuildThanks in honor of all who have helped rebuild communities in the wake of disasters MOORESVILLE, N.C. , April 22, 2025 /PRNewswire/ -- As Lowe's prepares to reopen its East Asheville store, which was heavily damaged by Hurricane Helene, the company's red vest associates are calling on communities nationwide to help share one million thank yous by May 2 to #BuildThanks for those who are helping communities across the nation rebuild after disasters. prnewswire.com - 2 months ago
Boundless Bio to Participate in the Needham Virtual Healthcare Conference SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Needham's Virtual Healthcare Conference. globenewswire.com - 2 months ago
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND submission expected in the first half of 2026 With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027 SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2024. “We made important strides in 2024 as we became a public company and continued to advance BBI-355, our oral, selective CHK1 inhibitor in the Phase 1/2 POTENTIATE trial in patients with oncogene amplified cancers, and we look forward to reporting preliminary proof-of-concept data in the second half of this year,” said Zachary Hornby, President and CEO of Boundless Bio. globenewswire.com - 3 months ago
Boundless Bio to Participate in the Leerink Global Healthcare Conference SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Leerink's Global Healthcare Conference. A fireside chat session is scheduled for Wednesday, March 12, 2025, in Miami, FL, at 11:20 a.m. globenewswire.com - 4 months ago
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer - Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer centers - - Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer centers - globenewswire.com - 4 months ago
January Effect Builds Up Momentum: 5 Small-Cap Stocks to Buy After logging its worst month, the Russell 2000 Index is up 0.4% in the initial week of 2025, indicating that the "January Effect" is building up momentum. zacks.com - 5 months ago
8. Profile Summary

Boundless Bio, Inc. BOLD

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 23.3 M
Dividend Yield 0.00%
Description Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Contact 9880 Campus Point Drive, San Diego, CA, 92121 https://boundlessbio.com
IPO Date July 20, 2016
Employees 64
Officers Ms. Jessica Oien J.D. Chief Legal Officer & Corporate Secretary Dr. Peter Krein Ph.D. Senior Vice President of Precision Medicine Ms. Meredith Wesley Senior Vice President of Talent & Culture Dr. James L. Freddo M.D. Interim Chief Medical Officer Ms. Sara Weymer Senior Vice President of Clinical Operations Ms. Amy Berkley Ph.D. Senior Vice President of Program Team Mr. David Hinkle Senior Vice President of Finance, Controller & Corporate Treasurer Mr. Anthony Pinkerton Ph.D. Senior Vice President of Drug Discovery Dr. Christian Hassig Ph.D. Chief Scientific Officer Mr. Zachary Hornby Chief Executive Officer, President & Director